Diabetes and Cardiovascular Disease Risk: The Hard Truth

Slides:



Advertisements
Similar presentations
Cardiovascular effects of anti-hyperglycemic therapy Edoardo Mannucci Diabetes Agency Careggi teaching hospital, Firenze, Italy.
Advertisements

Facts and Fiction about Type 2 Diabetes Michael L. Parchman, MD Department of Family & Community Medicine September 2004.
Canadian Diabetes Association 2013 Clinical Practice Guidelines Targets for Glycemic Control Chapter 8 S. Ali Imran, Rémi Rabasa-Lhoret, Stuart Ross.
ACCORD - Action to Control Cardiovascular Risk in Diabetes ADVANCE - Action in Diabetes to Prevent Vascular Disease VADT - Veterans Administration Diabetes.
Joint Effects of Routine Blood Pressure Lowering and Intensive Glucose Control ADVANCE Adapted from EASD 2008.
Session II: Glycemic control, when the lower is not the better Strict glycemic control and cardiovascular diseases Stefano Genovese Diabetologia e Malattie.
1 NHLBI/NEI National Institutes of Health NHLBI/NEI National Institutes of Health.
Cost-Effectiveness of Treatment Strategies for Comorbid Diabetes and Dyslipidemia Part 1.
Diabetes Mellitus 101 for Cardiologists (and Alike): 2015
Diabetes Mellitus 101 for Cardiologists (and Alike): 2015
An initiative of South Asian Federation of Endocrine Societies (SAFES)
Prevalence (%) estimates of diabetes (20-79 years) 2010.
Part 3. Diabetes Report Card: HbA 1c Levels in the United States Hoerger TJ, et al. Diabetes Care. 2008;31: Patients (%) HbA 1c (%)
R1 강민혜 / prof. 전숙. Introduction Patients with type 2 diabetes have a greatly increased risk of cardiovascular events. The morbidity and mortality related.
Blood Glucose, Lipids, and Coronary Artery Disease: Emerging Strategies for Multimechanistic Treatment.
Reducing Adverse Outcomes after ACS in Patients with Diabetes Goals
HOPE: Heart Outcomes Prevention Evaluation study
Diabetic Dyslipidemia in Practice
Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment:
The PPAR Journey: What Can We Expect in the Future?
The PPAR Journey: What Can We Expect in the Future?
Panelists. Type 2 Diabetes, Renal Impairment, and CHD: Reducing 2 Vascular Risks With 1 Stone.
The role of metabolic surgery in the management of obesity and t2dm
New Insights on PPAR Agonists For Cardiovascular Disease
Clinical Trials in Residual Cardiovascular Risk: A Fresh Perspective
Overview of Disparities
Cardiovascular Disease Risk Reduction Advances in Dyslipidemia
Systolic Blood Pressure Intervention Trial (SPRINT)
Modern Strategies for Basal Insulin Use in T2D
Clinical Advances in Type 2 Diabetes and Cardiovascular Risk
Early Type 2 Diabetes Mellitus: A Cardiovascular Disease
Incidence of CV Events in Subjects With T2D vs the Nondiabetic CAD Population
Impacting CV Risk With Diabetes Medications
Impacting CV Risk With Diabetes Medications
Panelists. Secondary Prevention of Macrovascular Events in Type 2 Diabetes: Focus on Dyslipidemia.
Diabetes Increases Risk of CVD
Improving Management of Type 2 Diabetes in Hispanic/Latino Patients
Evaluating LDL-C Recommendations
What's New in Dyslipidemia?
Statins and Glucose Metabolism: Are All Agents Alike?
Selected Causes of Cardiac Injury PEACE Trial High-Sensitivity Biomarker Substudy.
UKPDS 35: Impact of Increasing A1c on Cardiovascular Disease in T2DM
Cardiometabolic Risk: What Can the PPAR-Alpha Agonists Teach Us?
CV Risk Management in T2DM: What Did We Learn from ADA 2016?
Panelists. Secondary Prevention in Patients With ACS and Diabetes: How Can We Optimize Therapy?
Diabetes and Cardiovascular Disease Risk: The Hard Truth
Learning Objectives Metabolic Abnormalities Associated With T2D.
The Cardiologist's Mindset in the Management of Diabetes and Coronary Artery Disease: Today and Tomorrow.
Goals. Weight Management Goals and Approaches in Patients With Type 2 Diabetes.
Incidence of CV Events in Subjects With T2D vs the Nondiabetic CAD Population
Residual CV Risk in Patients With Dyslipidemia and Stable CAD
Definition of Elderly. Advanced Age and CV Risk: To Start or Not to Start a Statin in Older Patients?
Advances in Hypertriglyceridemia Treatment
T2DM, CV Risk, and Modulating Risk With Glucose-Lowering Strategies
CV Risk Reduction with Diabetes Drugs -- Should Cardiologists or Diabetologists Take the Lead?
Panelists. Cardiovascular Risk Modulation in Diabetes: Emerging Pathways and Insights.
Pharmacotherapy for Diabetic Coronary Disease:
Insulin in Diabetes Management: Effective Patient Selection Is Key
Liraglutide Shows CV Benefit: Clinical Perspectives on the LEADER Trial
Healthy With HIV.
Elevated Admission Plasma Glucose Following ACS
Intensity of statin treatment and possible lipid lowering treatment intolerance and/or ineffectiveness issues among patients with type 2 diabetes (aged.
New Lipid-Lowering Guidelines
Kaplan-Meier plot of incident CVD according to the treatment group over a 4-year period following intensification of diabetes therapy. Kaplan-Meier plot.
2015 EASD In Review: CV Risk management in t2dm
An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61
An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61
What's New in Oral Combination Therapy for Type 2 Diabetes?
Baseline predictors for risk of cardiovascular events or all-cause mortality among immigrants with language barriers (N = 87,707). *Adjustment for all.
Risk Stratification of Patients With Type 2 Diabetes: An Interpretation of the Latest Treatment Guidelines.
Presentation transcript:

Diabetes and Cardiovascular Disease Risk: The Hard Truth

Learning Objectives

DIGAMI 1: Mortality after AMI

Glucose Therapy Intensification (GTI) Among Patients with Diabetes

Intensive Treatment of T2DM: Macrovascular Complications

Impact of Intensive Therapy in T2DM

Meta-Analysis of Intensive vs Standard Care*

Recommendations for Treatment of T2DM

VA-HIT: Gemfibrozil Prevents Secondary CVD Events

SYNCHRONY: Effect of Aleglitazar on Cardiometabolic Parameters in T2DM

AleCardio: Aleglitazar in Patients With T2D and ACS*

Managing CV Risk in Patients with T2DM: Concluding Remarks

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2024 SlidePlayer.com Inc. All rights reserved.